3Willemze R, Kerl H, Sterry W et al. EORTC classification for primary cutaneous lymphomas:a proposal from the Cutaneous Lymphoma Study Group of European Organization for Research and Treatment of Cancer. Blood, 1997; 90 ( 1 ): 354～ 71
4Willemze R, Meijer M. EORTC clarification for primary cutaneous lymphomas: the best guide to good clinical management.Am J Dermatopathol, 1999;21(3) :265～73
5Willemze R, Beljaards RC. The spectrum of primary cutaneous CD30(Ki-1 ) positive lympholiferative disorders. A proposal for classification and guidelines for management and treatment. Am Acad Dermatol, 1993;28(7) :973
6Cerroni L, Signoretti S, Hofler G et al. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low grade malignant cutaneous B-cell lyrnphoma. Am J Surg Pathol,1997;21(11):1307～15
7Duncan LM, LeBoit PE. Are primary cutaneous immunocytoma and marginal zone lymphoma the same disease? Am J Surg Pathol,1997;21(11):1368～72
8Vermeer MH,Geelen FAMJ, van Haselen CW et al. Primary cutaneous large B-cell lymphoma of the legs: a distinct type of cuta neous B-cell lymphoma with an intermediate prognosis. Arch Der matol, 1999; 132( 11 ): 1304 ～ 8
9Kim YH, Hoppe RT. Mycosis fungoides and the Sezary syn drome. Semin Oncol, 1999; 26: 276～ 89
6Franchina M,Kadin ME,Abraham LJ.Polymorphism of the CD30 promoter microsatellite repressive element is associated with development of primary cutaneous lymphoproliferative disorders[J].Cancer Epidemiol Biomarkers Prey,2005,14(5):1 322-1 325.
7Vander Vegt B,Roos MA.The expression pattern of MUC1(EMA) is related to tumor characteristics and clinical outcome of invasive ductal breast carcinoma[J].Histopathol,2007,5 151(2):227-238.
